Cited by — Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort.
No admitted local citation edges point to this work yet.
